Neuromodulation Market Size, Share, Forecast Report, 2026-2035

Neuromodulation Market Size, Growth and Trends in 2026 to 2035

The global neuromodulation market size was estimated at USD 9.54 billion in 2025 and is expected to reach USD 21.37 billion by 2035, growing at a CAGR of 8.4% from 2025 to 2035.

Neuromodulation Market Outlook

• Market Growth Overview: The neuromodulation market is expected to grow significantly between 2026 and 2035, driven by the rising prevalence of chronic diseases, increasing global aging population, greater susceptibility to chronic illnesses, creating sustained demand for long term neuromodulation treatment, and high research and development investment. 
• Sustainability Trends: Sustainability trends involve eco-friendly and material innovation, technology advancements, miniaturization, and closed-loop and AI integration.  
• Major Investors: Major investors in the market include LivaNova PLC, Nevro Corp, Medtronic, Boston Scientific, and Abbott.

Neuromodulation Market Report Scope

Neuromodulation Market Segmental Insights

By Technology Insights

How did the Internal Neuromodulation Segment Dominate the Neuromodulation Market?

The internal neuromodulation segment is driven by the rapid innovation in AI-driven, closed-loop implantable devices that offer superior precision and patient convenience. These systems, particularly for SCS and DBS, provide targeted chronic care that reduces medication reliance while delivering long-term results for aging populations. Supported by strong clinical evidence and improved reimbursement, internal devices have become the global standard of care for managing complex neurological conditions and chronic pain.

How did the External Neuromodulation Segment Expect to Hold the Fastest-Growing Neuromodulation Market in the Coming Years?

The external neuromodulation segment is driven by the non-invasive, patient-friendly design, offering a surgical alternative with higher comfort and portability. These systems, such as TMS and TENS, provide a cost-efficient solution that lowers the barrier to entry for patients and healthcare systems in emerging markets. The shortage of regulatory pathways and the integration of home-care wearables with mobile health platforms for remote monitoring. 

By Application Insights

How did the spinal cord stimulation (SCS) segment account for the largest share in the Neuromodulation market?

The spinal cord stimulation (SCS) segment is driven by the rollout of AI-driven, closed-loop systems, such as Medtronic’s Inceptiv, which adjust stimulation in real-time to enhance patient outcomes. The robust healthcare infrastructure and clinical data prove its long-term cost-effectiveness over traditional pharmaceutical therapies. The neuromodulation market is the gold-standard treatment for chronic pain and failed back surgery syndrome.

How did the Deep Brain Stimulation (DBS) Segment Expect to Hold the Fastest-Growing Neuromodulation Market in the Coming Years?

The deep brain stimulation Devices (DBS) segment is driven by the rising prevalence of Parkinson’s disease and epilepsy in aging populations. Innovation is shifting toward smart closed-loop systems and directional leads that adjust stimulation in real-time, significantly reducing side effects while improving precision. With expanding indications for treatment-resistant depression and OCD, the market is seeing a surge in demand for these minimally invasive, rechargeable solutions.

Key Players in the Neuromodulation Market

• Medtronic: As a market leader, Medtronic dominates the neuromodulation sector with a vast, integrated portfolio covering spinal cord stimulation (SCS), deep brain stimulation (DBS), and sacral nerve stimulation to treat chronic pain and movement disorders. Its continuous R&D investments and high-volume manufacturing enable the development of advanced technology like closed-loop neurostimulators and adaptive programming.
• Boston Scientific Corporation: Boston Scientific maintains a strong position through high-innovation products like the WaveWriter Alpha spinal cord stimulator system and strategic acquisitions, such as Axonics for sacral neuromodulation. 
• Abbott: Abbott leverages a strong portfolio of BurstDR spinal cord stimulation and dorsal root ganglion (DRG) therapies, showing high adoption for addressing treatment-resistant pain. Through a balanced focus on global R&D and strategic acquisitions, the company strengthens its position in both developed and emerging markets with advanced, long-lasting stimulation devices.
• LivaNova: LivaNova is a specialized leader in vagus nerve stimulation (VNS) therapy, holding a dominant market share in treating drug-resistant epilepsy and treatment-resistant depression using systems like SenTiva and Symmetry. 
• Synapse Biomedical, Inc.: Synapse Biomedical focuses on specializing in respiratory electrical stimulation, notably with their FDA-approved NeuRx DPS system that treats diaphragmatic dysfunction. They contribute to the niche area of functional neuromodulation, focusing on diaphragm pacing to help patients with amyotrophic lateral sclerosis (ALS) and spinal cord injuries breathe better. 

Segments Covered in the Report

By Technology

• Internal Neuromodulation
  • Spinal Cord Stimulation
  • Deep Brain Stimulation
  • Vagus Nerve Stimulation
  • Sacral Nerve Stimulation
  • Gastric Electrical Stimulation
• External Neuromodulation
  • Transcutaneous Electrical Nerve Stimulation (TENS)
  • Transcranial Magnetic Stimulation (TMS)
  • Respiratory Electrical Stimulation (RES)

By Application

• Spinal Cord Stimulation Market, By Application
  • Failed Back Syndrome
  • Chronic Pain
  • Ischemia
• Deep Brain Stimulation Market, By Application
  • Parkinson’s Disease
  • Tremor
  • Depression
  • Other DBS Applications
• Sacral Nerve Stimulation Market, By Application
  • Urine Incontinence
  • Fecal Incontinence
• Vagus Nerve Stimulation Market, By Application
  • Epilepsy
  • Other VNS Applications
• Gastric Electrical Stimulation Market, By Application
  • Gastroparesis
  • Obesity
• Transcutaneous Electrical Nerve Stimulation Market, By Application
  • Treatment-resistant Depression
  • Other TENS Applications
• Transcranial Magnetic Stimulation Market, By Application
  • Depression
  • Migraine Headache
• Respiratory Electrical Stimulation Market, By Application
  • Spinal Cord Injury

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • RoE
• Asia Pacific
  • Japan
  • China
  • India
  • Rest of Asia Pacific
• Rest of the World
  • Latin America
  • Middle East and Africa